Abstract：【Objective】 To investigate the expression and clinical significance of carcinoembryonic antigen (CEA), carbohydrate antigen (CA125 and CA50) in patients with cardiac cancer . 【Methods】 A total of 80 patients with cardiac cancer were selected as the observation group. At the same time period, 80 healthy volunteers were enrolled as the control group. The serum levels of CA125, CA50 and CEA were measured and compared in the two groups. The differences of CA125, CA50 and CEA levels in patients with different staging of cardiac cancer were compared as well. 【Results】 Serum CA125, CA50 and CEA levels in the observation group were 52.35±5.17 U/mL, 7.34±1.32 U/mL, 3.46±0.92 ng/mL, respectively, which were higher than those of the control group (25.46±2.09 U/mL, 5.86. ±1.01 U/mL, 1.85±0.84 ng/mL, respectively). The differences were statistically significant ( P<0.01). The levels of CA125, CA50, and CEA levels were higher in cardiac cancer patients with clinical stage Ⅲ, medium and moderate and poorly differentiated histological grade, and with lymph node metastasis. There were no significant differences in CA125, CA50, and CEA levels between patients with different genders.Regression analysis of CEA level as a dependent variable showed that lymph node metastasis was a factor affecting CA125, CA50, and CEA levels in patients with cardiac cancer. 【Conclusion】 The expression levels of CA125, CA50 and CEA in patients with cardiac cancer are higher and are affected by lymph node metastasis.
王祥军, 田川, 张建设. 贲门癌患者血清CA125、CA50、CEA的变化及其意义[J]. 医学临床研究, 2020, 37(8): 1178-1180.
WANG Xiang-jun, TIAN Chuan, ZHANG Jian-she. Expression and Significance of CA125, CA50 and CEA in Patients with Cardiac Cancer. JOURNAL OF CLINICAL RESEARCH, 2020, 37(8): 1178-1180.
[1] 冯帅豪, 高社干, 陈晓杰, 等. miRNA-320d和FoxM1在贲门癌组织中表达相关性及临床价值分析[J].安徽医科大学学报, 2017, 52(2):194-198. [2] Fran a LKL, Bitencourt AGV, Graziano L, et al. Tumor size assessment of invasive breast cancers: which pathological features affect MRI-pathology agreement[J].Cancer Res,2018, 38(1):2-3. [3] 林文科, 吴吉芳, 郑志昂. 多种肿瘤标志物在胰腺癌中的诊断价值及相关性研究[J].中国免疫学杂志, 2017, 33(1):120-125. [4] Galuppini F, Bertazza L, Barollo S, et al. MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome[J].Virchows Arch,2017, 471(5):651-658. [5] 朱建峰. 血清肿瘤标志物联合检验在结直肠癌临床诊断中的应用价值探讨[J].中外医疗, 2018, 37(10):197-199. [6] 程凤菊, 王志虎, 程凤姣,等. 肿瘤标志物联合细胞角蛋白18、19检测在恶性肿瘤诊断中的价值[J].中国基层医药, 2018, 25(6):763-766. [7] 诸静文, 张洁, 叶柳青,等.血清CA19-9、CA50、CA242、CA125及CEA联合检测在Ⅰ～Ⅲ期可切除胰腺癌中的临床应用价值[J].现代实用医学, 2018, 30(09):14-16. [8] 林文科, 吴吉芳, 郑志昂. 多种肿瘤标志物在胰腺癌中的诊断价值及相关性研究[J].中国免疫学杂志, 2017, 33(1):120-125. [9] Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer[J].Invest New Drugs,2017, 35(4):1-8. [10] Luo G, Liu C, Guo M, et al. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer[J].Ann Surg,2017, 265(4):800-802.
2020, Vol. 37 
